Levodopa-responsive aromatic L-amino acid decarboxylase deficiency.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 14991824.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report three siblings, who were treated empirically with levodopa combined with carbidopa. There was an immediate therapeutic response. Biochemical investigation surprisingly showed the clinical phenotype to be caused by aromatic L-amino acid decarboxylase deficiency. Molecular characterization showed a homozygous point mutation (c.387 G-->A) in exon 3. Kinetic studies showed the mutation to decrease the binding affinity for the substrate. This, combined with structural modeling suggesting alteration of active site configuration, provided an explanation for the therapeutic response to levodopa.
Medical subject headings
- Antiparkinson Agents
- Aromatic-L-Amino-Acid Decarboxylases
- Developmental Disabilities
- Levodopa